The use of eculizumab in renal transplantation

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages

  Barnett, A Nicholas R ^a   Asgari, Elham ^b   Chowdhury, Paramit ^a   Sacks, Steven H ^a,b   Dorling, Anthony ^a,b   Mamode, Nizam ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Complement C5; Eculizumab; Graft rejection; Kidney transplantation; Transplantation immunology

Indexed keywords

BORTEZOMIB; ECULIZUMAB; MONOCLONAL ANTIBODY;

ANTIBODY MEDIATED REJECTION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; DRUG USE; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; NEISSERIA MENINGITIDIS; PANCREAS TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; GRAFT REJECTION; HEMOLYTIC UREMIC SYNDROME; HEMOLYTIC-UREMIC SYNDROME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84878657666     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12102     Document Type: Review

References (58)

1. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004: 5: 981.
2. Damman J, Schuurs TA, Ploeg RJ, Seelen MA. Complement and renal transplantation: from donor to recipient. Transplantation 2008: 85: 923.
3. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007: 18: 1046.
4. Asgari E, Zhou WD, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant 2010: 15: 486.
5. De Vries B, Matthijsen RA, Wolfs T, Van Bijnen A, Heeringa P, Buurman WA. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003: 75: 375.
6. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion - role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998: 97: 2259.
7. Wang H, Jiang JF, Liu WH et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005: 79: 1121.
8. Wang H, Arp J, Liu WH et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007: 179: 4451.
9. Rother RP, Arp J, Jiang J et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008: 8: 1129.
10. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol 2004: 172: 5143.
11. Alexion Pharma UK Ltd. Summary of Product Characteristics: Soliris (last updated on the eMC 20/07/2012). http://www.medicines.org.uk/emc/medicine/19966/SPC/soliris/ (accessed October 18, 2012).
12. Rosales A, Riedl M, Zimmerhackl LB. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010: 6: 504.
13. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009: 360: 542.
14. Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. Blood 2009: 114: 956.
15. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009: 9: 2644.
16. Chatelet V, Lobbedez T, Fremeaux-Bacchi V, Ficheux M, Ryckelynck JP, De Ligny BH. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transpl Proc 2010: 42: 4353.
17. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010: 55: 708.
18. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010: 89: 903.
19. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011: 26: 613.
20. Zlamy M, Hofer J, Elias J et al. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy. Pediatr Transplant 2012: 16: E246.
21. Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 2012: 35: 394.
22. Wilson C, Brown A, White S, Goodship T, Sheerin N, Manas D. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011: 92: e42.
23. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for preventing and curing post-transplant atypical hemolytic uremic syndrome (aHUS) recurrence. Am J Transplant 2012: 12: 154.
24. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012: 12: 1046.
25. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol: CJASN 2012: 7: 748.
26. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009: 9: 231.
27. Lonze BE, Dagher NN, Simpkins CE et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010: 10: 2154.
28. Barnett N, Hadjianastassiou V, Shaw O et al. Eculizumab for salvage in post-transplant Thrombotic Microangiopathy. British Transplantation Society Annual Congress; 2011.
29. Stewart Z, Collins T, Konkowski B, Reed A, Thomas C. Eculizumab rescue of ABO-incompatible kidney transplant with antibody-mediated rejection refractory to splenectomy and plasmapheresis. Am J Transplant 2012: 12: 80.
30. Noone D, Al-Matrafi J, Tinckam K et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012: 12: 2546.
31. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 2012: 12: 1643.
32. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report. Transpl Proc 2011: 43: 2097.
33. Biglarnia A-R, Nilsson B, Nilsson T et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011: 24: E61.
34. Galliford J, Chan K, Charif R et al. Eculizumab prevents allograft loss from acute antibody mediated rejection in the short and medium term. Am J Transplant 2012: 12: 83.
35. Barnett ANR, Hadjianastassiou VG, Shaw OJ et al. Eculizumab for salvage in post-transplant thrombotic microangiopathy. Transpl Int 2011: 24 (Suppl 2): 153.
36. Hadaya K, Ferrari-Lacraz S, Fumeaux D et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011: 11: 2523.
37. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011: 26: 1325.
38. Nester C, Stewart Z, Myers D et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011: 6: 1488.
39. Krid S, Roumenina L, Beury D et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012: 12: 1938.
40. Riedl M, Hofer J, Rosales A et al. Successful renal transplantation in a child with factor H associated atypical hemolytic uremic syndrome (aHUS) with prophylactic eculizumab treatment. Pediatr Nephrol 2010: 25: 510.
41. Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010: 362: 1746.
42. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010: 362: 1744.
43. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Investig 2003: 112: 1644.
44. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003: 12: 535.
45. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004: 10: 1222.
46. Oku K, Atsumi T, Bohgaki M et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009: 68: 1030.
47. Stegall MD, Diwan TS, Burns JM et al. Prevention of acute humoral rejection with C5 inhibition. Am J Transplant 2009: 9: 241.
48. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011: 11: 2405.
49. Gandhi MJ, Degoey SR, Raghavaiah S, Gloor JM, Stegall MD, Cornell LD. Decreased early acute humoral rejection in renal transplant patients following terminal complement inhibition. Hum Immunol 2010: 71: S133.
50. Cornell LD, Gloor JD, Nasr SH et al. Chronic humoral rejection despite C5 inhibition after positive-crossmatch kidney transplantation (plus XMKTx). Am J Transplant 2010: 10: 125.
51. Cohney SJ, Hughes P, Rosemary M et al. C5 inhibition with eculizumab to prevent antibody mediated rejection (AbMR) in patients with donor specific anti-HLA antibody (DSAb) and a positive cross match. Am J Transplant 2011: 11: 483.
52. Bentall A, Gandhi MJ, Cornell L et al. Early antibody mediated rejection despite inhibition of terminal complement. Am J Transplant 2012: 12: 150.
53. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press, 2011. (accessed November 11, 2011).
54. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris (R)) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008: 13: 993.
55. Bouts AH, Struijk GH, Rijkers GT, Davin J-C, Bemelman FJ. Meningococcal polysaccharide vaccine fails to protect a renal transplant recipient receiving eculizumab from developing meningococcal disease. Pediatr Transplant 2011: 15: 110.
56. Bouts A, Monnens L, Davin J-C, Struijk G, Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011: 26: 1919.
57. Cornell LD, Burns JM, Stegall MD. Prevention of endothelial activation with C5 inhibition in positive-crossmatch kidney transplants (plus XMKTx). Am J Transplant 2009: 9: 304.
58. Cornell LD, Popp LA, Fiedler WD, Dulek JM, Gloor JM, Stegall MD. Membrane attack complex (MAC) staining in renal allografts lack of increased staining during antibody-mediated rejection. Am J Transplant 2011: 11: 291.